Tenax Therapeutics filings document a Phase 3, development-stage pharmaceutical company developing cardiopulmonary therapies, including TNX-103 (oral levosimendan) for PH-HFpEF. Recent 8-K reports record financial results, clinical program updates for LEVEL and LEVEL-2, intellectual-property notices, and amendments to levosimendan license rights, including expanded worldwide rights for orally administered products.
Proxy and current-report filings also describe Nasdaq-listed common stock, executive appointments, employment and compensation arrangements, equity awards, governance matters, and named-executive pay disclosures. These records frame the company's capital structure, leadership responsibilities, material agreements, and clinical-stage operations around levosimendan development and commercialization rights.
TENAX THERAPEUTICS, INC. (TENX), the issuer, is the subject of BlackRock, Inc.’s report of beneficial ownership of 2,804,788 common shares, or 7.5% of the class, as of September 30, 2026. BlackRock reported sole voting power over 2,754,990 shares and sole dispositive power over 2,804,788 shares, with no shared voting or dispositive power.
The reported amount reflects certain BlackRock business units and subsidiaries and affiliates, excluding securities, if any, held by business units disaggregated from those reporting units. BlackRock stated that various persons may receive dividends or proceeds from sales, but no one person’s interest is more than 5% of TENAX’s outstanding common shares.
Tenax Therapeutics (TENX) common stock was purchased by private investment funds managed by ADAR1 Capital Management, LLC in three reported transactions: 336,528 shares at a weighted-average $1.5066 per share on October 19, 2026; 254,342 shares at $1.5952 on October 20; and 331,979 shares at $1.6588 on October 21. Each weighted-average price covered multiple trades within a reported range. The funds directly own the shares, which may be deemed indirectly beneficially owned by ADAR1 and Daniel Schneeberger, ADAR1’s sole manager. Each reporting person disclaims beneficial ownership except to the extent of any pecuniary interest. No Rule 10b5-1 plan is reported.
Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report beneficial ownership of Tenax Therapeutics, Inc. (TENX) common stock. Each cover page lists 1,362,730 shares, or 3.6% of the class, with shared voting and shared dispositive power; sole voting and dispositive power are each reported as zero.
The statement says the securities are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC and Israel A. Englander. It also says the disclosure is not, by itself, an admission of beneficial ownership by the reporting persons.
Sphera Funds Management Ltd., Sphera Global Healthcare GP Ltd. and Sphera Global Healthcare Management LP report beneficial ownership of Tenax Therapeutics, Inc. (TENX) common stock. Each reports 2,663,296 shares, or 7.09%, with shared voting and dispositive power over that amount. The reported percentage is based on 37,423,917 common shares outstanding as of July 28, 2026, and 127,600 shares underlying call option contracts exercisable within 60 days.
The securities are held directly by Sphera Global Healthcare Master Fund and Sphera Biotech Master Fund, L.P. The reporting persons state that investment management authority for both funds is delegated to Sphera Global Healthcare Management LP, and each disclaims beneficial ownership of the securities.
Amendment No. 5 concerning Tenax Therapeutics, Inc. common stock lists Dellora Investments Master Fund LP with beneficial ownership of 2,061,000 shares (5.5%), and Dellora Investments LP and Kevin Pyun each with 2,400,000 shares (6.4%). Each reporting person lists zero sole voting and sole dispositive power; shared voting and dispositive power are 2,061,000 shares for the Master Fund and 2,400,000 shares for Dellora Investments LP and Pyun.
The percentages use 37,423,917 shares outstanding as of July 28, 2026. Dellora Investments LP, an investment adviser to private funds, and Pyun, its principal, may be deemed beneficial owners of fund-held shares, but both disclaim beneficial ownership. The Funds have the right to receive or direct dividends and sale proceeds from the shares.
Tenax Therapeutics, Inc. temporarily paused enrollment in its LEVEL-2 Phase 3 trial and intends to amend eligibility criteria to focus on patients with baseline 6MWD of 100–300 m, or above 300 through 400 m with RAVI of at least 25 mL/m². Enrollment may resume at each site as the amended protocol goes into effect there. Tenax requested a Type C meeting with the FDA to discuss the overall development of levosimendan.
In the completed LEVEL Phase 3 trial, levosimendan did not meet its primary endpoint: the Week 12 6MWD treatment difference was 3.5 m (p=0.63). In the prespecified subgroup with baseline 6MWD below 333 m, the treatment difference versus placebo was 26.3 m (95% CI: 6.0–46.7; nominal p=0.0112). Overall NT-proBNP was reduced 49% versus placebo (nominal p<0.0001). Treatment-related adverse events were reported in 38.3% of TNX-103 patients versus 17.4% of placebo patients; serious adverse events were reported in 10.8% and 10.7%, respectively.
TENAX THERAPEUTICS, INC. (TENX) director Declan Doogan reported a purchase of 53,000 shares of common stock on September 16, 2026 at $1.92 per share in an open-market or private transaction. Following this trade, he directly holds 55,274 common shares.
He also reports direct holdings of several stock options (rights to buy common stock) with exercise prices ranging from $5.75 to $3,200.00 per share and expiration dates between June 10, 2031 and January 9, 2036, covering underlying common shares in multiple option grants.
TENAX THERAPEUTICS, INC. (TENX) reports that CEO and director Christopher Thomas Giordano purchased a total of 10,850 shares of common stock in two transactions on September 11 and September 15, 2026, at weighted average prices of about $1.88 and $1.82 per share. No Rule 10b5-1 trading plan is reported, and the filing also lists multiple existing stock option awards over several years with vesting schedules tied to continued employment.
TENAX THERAPEUTICS, INC. (TENX) reported that Chief Financial Officer Thomas R. Staab II purchased 5,675 shares of common stock in the open market on September 11, 2026 at a weighted average price of $1.935 per share, bringing his direct common stock holdings to 15,675 shares.
He also holds a stock option covering 450,000 shares of common stock at an exercise price of $11.95 per share, expiring on May 11, 2036; according to the vesting schedule, 25% vest on May 11, 2027 and the remainder vest in substantially equal monthly installments over 36 months, subject to continued employment. No Rule 10b5-1 trading plan is reported.
Tenax Therapeutics, Inc. (TENX) received an amended Schedule 13G/A from ING Groep N.V. and ING Capital Markets LLC reporting that, as of September 11, 2026, they no longer beneficially own any shares of Tenax common stock. All reported voting and dispositive powers have been reduced to zero.
The ownership percentages are calculated against 37,423,917 shares of Tenax common stock outstanding as of July 28, 2026, as referenced from Tenax’s Quarterly Report for the period ended June 30, 2026.